Cancer Letters
Volume 291, Issue 1 , Pages 39-45 , 1 May 2010

Dysfunction of natural killer cells in patients with transitional cell carcinoma

  • Chang-Te Lin

      Affiliations

    • Department of Urology, Chia-Yi Christian Hospital, National Chung Cheng University, Chia-Yi, Taiwan
    • These two authors contributed equally to this work.
    • ,
  • Min-Tsung Yu

      Affiliations

    • Institute of Molecular Biology, National Chung Cheng University, Chia-Yi, Taiwan
    • These two authors contributed equally to this work.
    • ,
  • Chin Li

      Affiliations

    • Department of Life Science, National Chung Cheng University, Chia-Yi, Taiwan
    • Institute of Molecular Biology, National Chung Cheng University, Chia-Yi, Taiwan
    • ,
  • Yun-Che Ho

      Affiliations

    • Institute of Molecular Biology, National Chung Cheng University, Chia-Yi, Taiwan
    • ,
  • Cheng-Huang Shen

      Affiliations

    • Department of Urology, Chia-Yi Christian Hospital, National Chung Cheng University, Chia-Yi, Taiwan
    • ,
  • Dai-Wei Liu

      Affiliations

    • Department of Medicine, Tzu Chi University, Hualien, Taiwan
    • ,
  • De-Ching Chang

      Affiliations

    • Department of Life Science, National Chung Cheng University, Chia-Yi, Taiwan
    • ,
  • Shu-Fen Wu

      Affiliations

    • Department of Life Science, National Chung Cheng University, Chia-Yi, Taiwan
    • Institute of Molecular Biology, National Chung Cheng University, Chia-Yi, Taiwan
    • Corresponding Author InformationCorresponding author. Address: 168 University Rd., Min-Hsiung, Chia-Yi 62102, Taiwan, ROC. Tel.: +886 5 2720411 66509; fax: +886 5 2722871.

Received 4 August 2009 ,Revised 23 September 2009 ,Accepted 28 September 2009.

References 

  1. Cerwenka A, Lanier LL. Natural killer cells viruses and cancer. Nat. Rev. Immunol. 2001;1:41–49
  2. Arnon TI, Markel G, Mandelboim O. Tumor and viral recognition by natural killer cells receptors. Semin. Cancer Biol. 2006;16:348–358
  3. Dunn GP, Koebel CM, Schreiber RD. Interferon’s, immunity and cancer immunoediting. Nat. Rev. Immunol. 2006;6:836–848
  4. Soiffer RJ, Murray C, Shapiro C, Collins H, Chartier S, Lazo S, et al. Expansion and manipulation of natural killer cells in patients with metastatic cancer by low-dose continuous infusion and intermittent bolus administration of interleukin 2. Clin. Cancer Res. 1996;2:493–499
  5. In:  Stewart BW,  Kleihues P editor. World Cancer Report. Lyon: IARC press; 2003;
  6. Murta-Nascimento C, Schmitz-Drager BJ, Zeegers MP, Steineck G, Kogevinas M, Real FX, et al. Epidemiology of urinary bladder cancer: from tumor development to patient’s death. World J. Urol. 2007;25:285–295
  7. Jaeger N, Radeke HW, Adolphs HD, Penkert A, Bertermann H, Vahlensieck W. Value of intravesical sonography in tumor classification of bladder carcinoma. Eur. Urol. 1986;12:76–84
  8. Totterman TH, Loskog A, Essand M. The immunotherapy of prostate and bladder cancer. BJU Int. 2005;96:728–735
  9. Nakamura H, Mukai M, Komatsu K, Tanaka-Okamoto M, Itoh Y, Ishizaki H, et al. Transforming growth factor-beta1 induces LMO7 while enhancing the invasiveness of rat ascites hepatoma cells. Cancer Lett. 2005;220:95–99
  10. Denys H, Derycke L, Hendrix A, Westbroek W, Gheldof A, Narine K, et al. Differential impact of TGF-beta and EGF on fibroblast differentiation and invasion reciprocally promotes colon cancer cell invasion. Cancer Lett. 2008;266:263–274
  11. Fujieda S, Sunaga H, Tsuzuki H, Fan GK, Saito H. IL-10 expression is associated with the expression of platelet-derived endothelial cell growth factor and prognosis in oral and oropharyngeal carcinoma. Cancer Lett. 1999;136:1–9
  12. Fortis C, Foppoli M, Gianotti L, Galli L, Citterio G, Consogno G, et al. Increased interleukin-10 serum levels in patients with solid tumours. Cancer Lett. 1996;104:1–5
  13. Milano F, Jorritsma T, Rygiel AM, Bergman JJ, Sondermeijer C, Ten Brinke A, et al. Expression pattern of immune suppressive cytokines and growth factors in oesophageal adenocarcinoma reveal a tumour immune escape-promoting microenvironment. Scand J. Immunol. 2008;68:616–623
  14. Rabinovich GA, Gabrilovich D, Sotomayor EM. Immunosuppressive strategies that are mediated by tumor cells. Annu. Rev. Immunol. 2007;25:267–296
  15. Hudig D, Djobadze M, Redelman D, Mendelsohn J. Active tumor cell resistance to human natural killer lymphocyte attack. Cancer Res. 1981;41:2803–2808
  16. Izadifar V, de Boer WI, Muscatelli-Groux B, Maille P, van der Kwast TH, Chopin DK. Expression of transforming growth factor beta1 and its receptors in normal human urothelium and human transitional cell carcinomas. Hum. Pathol. 1999;30:372–377
  17. Hung TT, Wang H, Kingsley EA, Risbridger GP, Russell PJ. Molecular profiling of bladder cancer: involvement of the TGF-beta pathway in bladder cancer progression. Cancer Lett. 2008;265:27–38
  18. Laouar Y, Sutterwala FS, Gorelik L, Flavell RA. Transforming growth factor-beta controls T helper type 1 cell development through regulation of natural killer cell interferon-gamma. Nat. Immunol. 2005;6:600–607
  19. Lin CY, Chuang TF, Liao KW, Huang YJ, Pai CC, Chu RM. Combined immunogene therapy of IL-6 and IL-15 enhances anti-tumor activity through augmented NK cytotoxicity. Cancer Lett. 2008;272:285–295
  20. North J, Bakhsh I, Marden C, Pittman H, Addison E, Navarrete C, et al. Tumor-primed human natural killer cells lyse NK-resistant tumor targets: evidence of a two-stage process in resting NK cell activation. J. Immunol. 2007;178:85–94
  21. Goldberg JE, Sherwood SW, Clayberger C. A novel method for measuring CTL and NK cell-mediated cytotoxicity using annexin V and two-color flow cytometry. J. Immunol. Methods. 1999;224:1–9
  22. Derby E, Reddy V, Kopp W, Nelson E, Baseler M, Sayers T, et al. Three-color flow cytometric assay for the study of the mechanisms of cell-mediated cytotoxicity. Immunol. Lett. 2001;78:35–39
  23. Lee JC, Lee KM, Kim DW, Heo DS. Elevated TGF-beta1 secretion and down-modulation of NKG2D underlies impaired NK cytotoxicity in cancer patients. J. Immunol. 2004;172:7335–7340
  24. Thomas DA, Massague J. TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. Cancer Cell. 2005;8:369–380
  25. Yang MH, Chen KK, Yen CC, Wang WS, Chang YH, Huang WJ, et al. Unusually high incidence of upper urinary tract urothelial carcinoma in Taiwan. Urology. 2002;59:681–687
  26. Eder IE, Stenzl A, Hobisch A, Cronauer MV, Bartsch G, Klocker H. Transforming growth factors-beta1 and beta2 in serum and urine from patients with bladder carcinoma. J. Urol. 1996;156:953–957
  27. Loskog A, Ninalga C, Paul-Wetterberg G, de la Torre M, Malmstrom PU, Totterman TH. Human bladder carcinoma is dominated by T-regulatory cells and Th1 inhibitory cytokines. J. Urol. 2007;177:353–358
  28. Dasgupta S, Bhattacharya-Chatterjee M, O’Malley BW, Chatterjee SK. Inhibition of NK cell activity through TGF-beta1 by down-regulation of NKG2D in a murine model of head and neck cancer. J. Immunol. 2005;175:5541–5550
  29. Borg C, Jalil A, Laderach D, Maruyama K, Wakasugi H, Charrier S, et al. NK cell activation by dendritic cells (DCs) requires the formation of a synapse leading to IL-12 polarization in DCs. Blood. 2004;104:3267–3275
  30. Granucci F, Zanoni I, Pavelka N, Van Dommelen SL, Andoniou CE, Belardelli F, et al. A contribution of mouse dendritic cell-derived IL-2 for NK cell activation. J. Exp. Med. 2004;200:287–295

PII: S0304-3835(09)00618-1

doi: 10.1016/j.canlet.2009.09.019

Cancer Letters
Volume 291, Issue 1 , Pages 39-45 , 1 May 2010

Article Tools

* Image Usage & Resolution